Skip to main content
OpenTrials

Clinical trial condition

Relapsed/Refractory Mantle Cell Lymphoma

Explore clinical trials studying Relapsed/Refractory Mantle Cell Lymphoma. Study availability and eligibility vary by location and protocol.

7 public trials 0 recruiting studies
Refine in advanced search Browse all conditions

Relapsed/Refractory Mantle Cell Lymphoma trial results

Active, not recruiting

Study of KTE-X19 in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma or Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia

NCT06253663

Conditions
Disease Attributes, Hemic and Lymphatic Diseases, Immune System Diseases, +13 more
Locations
  • Chiba University Hospital Chiba, Japan
  • Kyushu University Hospital Fukuoka, Japan
  • Hokkaido University Hospital Hokkaido, Japan
  • Kyoto University Hospital Kyoto, Japan
View Trial Details
Completed

Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 3)

NCT04880434

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +8 more
Locations
  • Banner MD Anderson Cancer Center Gilbert, Arizona, United States
  • Stanford University Palo Alto, California, United States
  • University California Los Angeles (UCLA) Santa Monica, California, United States
  • Sarah Cannon- Denver Denver, Colorado, United States
View all 40 locations
View Trial Details
Completed

Lenalidomide With or Without Idelalisib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma

NCT01838434

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +8 more
Locations
  • University of Chicago Chicago, Illinois, United States
  • Washington University School of Medicine St Louis, Missouri, United States
  • Roswell Park Cancer Institute Buffalo, New York, United States
  • Ohio State University Medical Center Columbus, Ohio, United States
View Trial Details
Completed

Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 1 and Cohort 2)

NCT02601313

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +8 more
Locations
  • Banner MD Anderson Gilbert, Arizona, United States
  • City of Hope Duarte, California, United States
  • University California Los Angeles (UCLA) Santa Monica, California, United States
  • Stanford University Stanford, California, United States
View all 32 locations
View Trial Details
Completed

A Study of PRT543 in Participants With Advanced Solid Tumors and Hematologic Malignancies

NCT03886831

Conditions
Adenocarcinoma, Adenoid Cystic Carcinoma, Anemia, +39 more
Locations
  • Banner MD Anderson Cancer Center Gilbert, Arizona, United States
  • UCSF Precision Cancer Medicine Building San Francisco, California, United States
  • Christiana Care Health Services, Christiana Hospital Newark, Delaware, United States
  • Florida Cancer Specialists Lake Mary, Florida, United States
View all 23 locations
View Trial Details
Completed

A Trial of Ibrutinib, Lenalidomide and Rituximab for Patients With Relapsed/Refractory Mantle Cell Lymphoma

NCT02460276

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +8 more
Locations
  • Rigshospitalet Copenhagen, Denmark
  • Helsinki University Hospital Helsinki, Finland
  • Norwegian Radium Hospital Oslo, Norway
  • Lund University Hospital Lund, Sweden
View Trial Details

Related conditions